Not rendering correctly? View this email as a web page here.

- May 2018 -


CLSI's Amgen Bay Area BioGENEius Recognizes Outstanding Students

READ Press Release >>


  • Inflammatix (FAST Fall 2017) is named a finalist in Fast Company’s 2018 World Changing Ideas Awards for its novel HostDx™ tests | Read More
  • An interview with Andre Watson, CEO of Ligandal (FAST Spring 2016) on Personalized Gene Therapy | Watch Here
  • Eidos Therapeutics (FAST Spring 2016) announced commencement of Phase 2 clinical trial to assess lead candidate AG10 in patients with symptomatic transthyretin amyloidosis (ATTR) cardiomyopathy | Read More
  • GigaGen (FAST Spring 2015) announced appointment of Sheila M. Keating, PhD, as Director of Immunology to lead GigaGen’s recombinant hyperimmune gammaglobulin to the clinic | Read More
  • Sandstone Diagnostics (FAST Fall 2013), makers of the Trak® Fertility suite of at home male reproductive health products, announced a military and veterans discount program in honor of May’s Military Appreciation Month | Read More

About FAST Advisory Program

The FAST Advisory Program provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Experienced entrepreneurs, product and business experts (which may include clinical development, regulatory, reimbursement and business development specialists) will advise selected Fellows during a twelve-week program, culminating in a Final FAST Showcase to a broad audience that includes potential investors and partners.

For information on the FAST program, contact Steve Karp at or Julie Harness at

Upcoming Events & Key Dates
5/10  CLSI Innovation Series: Managing Successful Growth & Considerations For Executives, South San Francisco, CA Register Here
5/10  Meet with 5AM Ventures, JLabs, South San Francisco Register Here
5/10  Expanded Access West Coast Symposium, San Francisco, CA Register Here
5/14-15  Health Technology Forum Innovation Conference 2018, Palo Alto, CA Register Here
5/15  QB3 Seminar: Why do Diagnostic Companies Fail? UCSF Mission Bay Register Here
5/17  JLabs and MilliporeSigma Discussion Panel: Navigating Technical and Regulatory Challenges with Confidence, South San Francisco Register Here
5/22  World Class Innovation, World Class Path-to-Market, JLabs South San Francisco Register Here
5/22  LTEN Network After Work Mixer, South San Francisco, CA Register Here
6/1  Deadline to Submit JLabs Quickfire Challenge: Health Technology Innovator Challenge: Mobile Wellness Management Apply Here
6/4  Redefining Early Stage Investments (RESI) Conference, Boston, MA Register Here
6/4-7  BIO International Convention 2018, Boston, MA Register Here
6/5  Meet with Pappas Capital, JLabs, South San Francisco Register Here
6/5  Rosenman Institute D-Series: How to Craft your Strategy for Federal Funding, UCSF Mission Bay Register Here
6/20 5th Annual Rosenman Symposium, UCSF Mission Bay Register Here
6/21 UC Berkeley Skydeck Angel Investor Panel, Berkeley, CA Contact Bree Cahill for more info:



  • CLSI Hosts CARB-X Information and Networking Session: San Diego | Read More 
  • Powered by CARB-X company, Spero Therapeutics appointed Ian A. Critchley, as Head of Clinical Microbiology to lead Spero’s pre-clinical and clinical microbiology efforts | Read More
  • Powered by CARB-X company, Amicrobe appointed Doug Looker, as Vice President of Preclinical Development and Manufacturing in anticipation of product trials Read More
  • Amicrobe also just announced filing of international PCT patent application focused on safety in the treatment of antibiotic resistant infections | Read More
  • Powered by CARB-X company, VenatoRx Pharmaceuticals founders Christopher J. Burns, Luigi Xerri, and Daniel Pevear are named EY Entrepreneur of the Year 2018 Finalists in the Greater Philadelphia Area | Read More
  • Powered by CARB-X company, Entasis Therapeutics announced an exclusive license agreement with Shanghai based biopharmaceutical company, Zai Lab, for a collaborative development of ETX2514 in the Asia-Pacific region | Read More
  • CARB-X awards up to $9 million to Switzerland based company Idorsia to support the development of a new class of antibiotic, a novel dual-acting topoisomerase inhibitor, to treat patients with infections caused by drug-resistant bacteria | Read More
  • CARB-X announces award up to $12 million to Achaogen to support the development of a next-generation broad-spectrum aminoglycoside antibiotic capable of overcoming resistance mechanisms and potentially treating highly-resistant pathogens | Read More
  • Powered by CARB-X company, Oppilotech announced it has been selected for funding for Innovate UK grant to expand their model to incorporate peptidoglycan in cell wall of bacteria | Read More
  • Powered by CARB-X company, Iterum files for $92M IPO to support their Phase 3 clinical trials of oral and intravenous versions of antibiotic sulopenem | Read More
  • CARB-X awards up to $6.2 million to Melinta Therapeutics to support the development of a new class of antibiotic called pyrrolocytosine to treat the most serious drug-resistant bacterial infections Read More

Other AMR News

  • French microbiology company, Deinove acquired Morphochem’s Phase II C. diff FDA Fast-Track antibiotic compound | Read More
  • After getting FDA breakthrough device designation, 3i Diagnostics is eyeing hospital microbiology labs for its infrared POC platform | Read More
  • According to a new study from Columbia University, mice in New York City apartment buildings are carrying antibiotic-resistant bugs and viruses that have never been seen before | Read More
  • The United Kingdom and India agreed to extend a health partnership by sharing research, knowledge and technology in areas of anti-microbial resistance in low cost health products and high yield crops | Read More
  • Read a Q&A with Dame Sally Davies, chief medical officer for England and chief medical advisor to the UK government, who discusses pharmacists’ centrality to reducing careless use of antibiotics | Read More
  • X-Biotix Therapeutics, a biotechnology company developing small molecule antibiotic scaffolds for multi-drug resistant Gram-negative pathogens, announced the company has secured $7 million in a Series A financing to advance its pipeline of novel antibiotic candidates | Read More
  • British Society for Antimicrobial Chemotherapy published a free e-book on Antimicrobial Stewardship: From Principles to Practice | Download Here
  • Longitude Prize: Fighting Superbugs in India: A Short film that follows the stories from India where antibiotic resistance is growing at a rapid rate | Watch Here
  • University of Bristol researcher, Dr. Borko Amulic was awarded £1.2 million by the Medical Research Council (MRC) to lead research of how neutrophil immune cells can be boosted to fight infection in the post-antibiotic age | Read More
  • A large study of nearly 200,000 children in three African countries show that two doses a year of an antibiotic can sharply cut infant death rates by as much as 25 percent | Read More
  • Will the next superbug come from Yemen? A 22-year old college student from Yemen survived a deadly drug-resistant infection, caused by the bacterium, Acinetobacter baumannii | Read More
  • Bacteria’s ability to eat drugs that are supposed to kill them, may be a powerful weapon against antibiotic resistance | Read More
  • The AMR community mourns the passing of Stanley Falkow, an enormously influential microbiologist whose inspiring mentorship created the field of molecular microbial pathogenesis | Read More

 About CARB-X


CARB-X is one of the world's largest public-private partnership devoted to early stage antibacterial R&D. Funded by ASPR/BARDA and Wellcome Trust, with in-kind support from NIAID, CARB-X is investing up to $455 million from 2016-2021 to support innovative products from ‘hit-to-lead’ phase through Phase 1 clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X operates through Boston University. Other partners include RTI International, the Broad Institute of Harvard and MIT, MassBio, and the California Life Sciences Institute (CLSI).

For more information on CARB-X, please contact Heather Shane,

Upcoming Events
5/28-29 Countering Antimicrobial Resistance, Beijing, China Register Here
6/7-11 ASM Microbe, Atlanta Register Here
6/12 DARPA Folded Non-Natural Polymers with Biological Function Program, San Francisco, CA More Info
6/14 Duke-Margolis – important public meeting focused on Understanding the Development Challenges Associated with Emerging Non-Traditional Antibiotics More Info
7/16-20 Short course | AMR: a multidisciplinary approach, London, UK More Info and Apply Here
7/22-27 Gordon Research Conference on Drug Resistance for Cancer, Infectious Disease and Agriculture, Smithfield, RI Register Here
9/20 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Lisbon, Portugal Register Here


 STEM Education & Careers 

  • CLSI partner, NexGeneGirls begin 2018 Spring Bootcamp | Read More
  • Biotech Primer Article: $8.7 Billion SMA Drug Explained | Read More
  • Biotech Primer Article: Papa's Got a Brand New Lab Coat | Read More
  • Biotech Primer Article: Ticked Off: The Science Behind Lyme Disease | Read More

About CLSI Education & Career Programs

CLSI helps build the next generation of life science professionals by bringing industry and institutions of learning together to improve STEM education in California and to inspire and develop life science careers. CLSI also works to ensure that the current and anticipated talent needs of the industry are met, and that the workforce pipeline for the industry remains strong.

Upcoming Events
5/16 SFSU MBA Information Session Lunch & Learn for Biotech Professionals More Info
5/24-25 BioBasics: Biotech For The Non-Scientist, South San Francisco, CA Register Here
5/31 SF State University Personalized Medicine 11.0 Conference, South San Francisco, CA Register Here
6/20 Understanding Drug Pricing And Reimbursement, South San Francisco, CA Register Here
9/20-21 BioBasics: Biotech For The Non-Scientist, South San Francisco, CA Register Here



California Life Sciences Institute (CLSI) supports the foundations of innovation that have made California home to the world’s most prominent life sciences ecosystem. Our mission is to maintain California’s leadership in life sciences innovation through support of entrepreneurship, education and career development. CLSI also serves as an accelerator for CARB-X, the world’s largest public-private partnership devoted to early stage antibacterial R&D.

CLSI is an affiliate of the California Life Sciences Association (CLSA), which represents California’s leading life sciences organizations. The California Life Sciences Institute is a non-profit 501(c)(3), and was established in 1990 as the BayBio Institute.